Macquarie Group LTD Aerie Pharmaceuticals Inc Transaction History

Macquarie Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $2,535 - $6,061	-398 Reduced 7.24%	5,100 $83,000
Q3 2021 Nov 12, 2021	SELL	$11.32 - $16.63 $2.12 Million - $3.12 Million	-187,569 Reduced 97.15%	5,498 $63,000
Q1 2021 May 14, 2021	BUY	$13.12 - $20.9 $2.46 Million - $3.92 Million	187,381 Added 3295.48%	193,067 $3.45 Million
Q2 2020 Aug 11, 2020	BUY	$12.0 - $16.13 $7,032 - $9,452	586 Added 11.49%	5,686 $84,000
Q1 2019 May 15, 2019	SELL	$36.32 - $49.25 $2.02 Million - $2.74 Million	-55,574 Reduced 91.59%	5,100 $242,000
Q4 2018 Feb 15, 2019	SELL	$33.0 - $60.04 $660,000 - $1.2 Million	-20,000 Reduced 24.79%	60,674 $2.19 Million
Q3 2018 Nov 15, 2018	BUY	$56.15 - $73.9 $372,892 - $490,769	6,641 Added 8.97%	80,674 $4.97 Million
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $408,351 - $601,220	8,534 Added 13.03%	74,033 $5 Million
Q1 2018 May 11, 2018	BUY	$51.15 - $61.0 $658,760 - $785,619	12,879 Added 24.48%	65,499 $3.55 Million
Q4 2017 Feb 15, 2018	BUY	$50.85 - $65.1 $1.11 Million - $1.42 Million	21,860 Added 71.07%	52,620 $3.14 Million
Q3 2017 Nov 08, 2017	BUY	$48.6 - $60.1 $1.49 Million - $1.85 Million	30,760	30,760 $1.5 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.